IACUC Policy 03: Complete Freund’s Adjuvant (CFA) Use

Policy Purpose: The intent of this policy is to describe the use of adjuvants at TTU.

Table of Contents

1. Introduction
2. Policy
3. Procedures
4. References

1. Introduction
   a. The use of adjuvants in animal research requires careful consideration, particularly Complete Freund’s Adjuvant (CFA). This compound can cause severe side effects, such as nonspecific inflammation. Alternatives to CFA should be used whenever possible. However, use of CFA may be scientifically justified in certain circumstances such as, induction of autoimmune disease models.

2. Policy
   a. The use of adjuvants must be reviewed and approved by the IACUC. Scientific justification is required for the use of any adjuvant (e.g., CFA) that could induce a severe reaction or cause local and/or systemic pain and distress to the animal.
   b. When consistent with the scientific objectives (e.g. routine antibody collection) adjuvants known to produce less intense inflammatory responses must be considered as alternatives to CFA.
   c. CFA should be used responsibly and with care in order to avoid or minimize the adverse effects of excessive inflammation. In most instances, CFA is necessary only for initial immunization, while Incomplete Freund's Adjuvant, which lacks mycobacteria, is the adjuvant of choice for subsequent immunizations. Successive immunizations with CFA must be scientifically justified and approved by the IACUC.
   d. Whenever possible, the least invasive route of administration is required to accomplish the experimental goal. Intra-dermal, intramuscular, and footpad injections should be avoided unless scientifically justified.
   e. Unless scientifically justified, footpad inoculation must not be used for routine immunization of rodents. Rabbit immunization via feet must not occur because they lack a true footpad.

3. Procedures
   a. Guidelines for preparation and administration should assist to eliminate or minimize complications due to administration of CFA
      i. Utilization of sterile techniques in the preparation of antigen-adjuvant emulsions within a class II biological safety cabinet.
      ii. Aseptic preparation of the injection site
      iii. Appropriate injection technique
      iv. Appropriate routes and sites of administration (See Table 1)
         a. A period of 2 weeks minimum between subsequent inoculations is recommended.
         b. In addition to the route of administration, the site of injection should be chosen with care in order to avoid areas that may compromise the normal movement or handling of the animal (e.g., intradermal injections in the scruff of the neck of a rabbit).
      v. Adequate separation of injection sites
         a. It is necessary to separate multiple injection sites by a distance sufficient to avoid coalescence of inflammatory lesions.
vi. Use of smaller volumes and concentrations at each injection site
   a. Formulations of CFA containing 0.5 mg/ml of mycobacterial components are commercially
      available and have been successfully used by many researchers. However, concentrations of
      < 0.1 mg/ml are recommended in order to minimize the inflammation and necrosis observed
      with higher concentrations. Some protocols, such as autoimmune disease induction protocols,
      may require the use of greater concentrations than those available commercially.
   b. For favorable results using CFA while minimizing undesirable side effects, use the
      recommended injection volumes and sites appropriate for the species, size of the animal, and
      experimental goal (see Table 1). Some routes of injection may potentially be less disruptive
      to the animal than other routes (e.g., subcutaneous injection vs. foot-pad administration).

b. Post-injection observations
   i. As a result of CFA injection, pain and distress or injection site complication may occur. Animals
      should be observed post injection for up to 4 weeks minimum. Supportive care may include topical
      cleaning, antibiotics or analgesics.
   ii. If the animal is experiencing obvious pain or distress, the AV should consider narcotic opioids for
      analgesic (taking into account the research objective).

c. Personnel Safety
   i. CFA contains mycobacterial components and could present an occupational hazard to laboratory
      personnel that would be preparing or administering the agent.
   ii. Laboratory personnel should be appropriately trained to handle, administer and dispose of the
      product.
   iii. Minimum PPE includes gloves and safety glasses.
   iv. Accidental needle punctures have resulted in clinical pain, inflammatory lesions and abscesses in
      individuals which are tuberculin-positive. Accidental CFA exposure has also resulted in tuberculin-
      negative individuals subsequently testing positive to TB tests. In the event of a needle stick, contact
      EHS (806) 742-3876.
   v. Institutional Biosafety Committee (IBC) approval may be required for CFA use. Contact the IBC at
      ibc.ehs@ttu.edu for additional information.

Table 1. Recommended Volume (ml) of Adjuvant-Antigen Emulsion per Site According to Species

<table>
<thead>
<tr>
<th>Species</th>
<th>SubQ</th>
<th>Intradermal</th>
<th>Intraperitoneal</th>
<th>Footpad</th>
<th>Intramuscular</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mouse</td>
<td>&lt;0.1</td>
<td>Not permitted</td>
<td>&lt;0.2</td>
<td>&lt;0.05*</td>
<td>Not recommended</td>
</tr>
<tr>
<td>Rat</td>
<td>&lt;0.1</td>
<td>&lt;0.05* Not recommended</td>
<td>&lt;0.5</td>
<td>&lt;0.1*</td>
<td>Not recommended</td>
</tr>
<tr>
<td>Rabbit</td>
<td>&lt;0.25</td>
<td>&lt;0.05*</td>
<td>Not permitted</td>
<td>Not permitted</td>
<td>&lt;0.5**</td>
</tr>
<tr>
<td>Pig</td>
<td>-</td>
<td>-</td>
<td>Not recommended</td>
<td>-</td>
<td>1.0</td>
</tr>
</tbody>
</table>

* Only when justified scientifically
** Only one limb recommended unless justified scientifically

4. References

- PHS Policy on Humane Care and Use of Laboratory Animals
- Guide for the Care and Use of Laboratory Animals, 8th Edition
- http://www.ohsu.edu/xd/about/services/integrity/policies/upload/Adjuvant-use-2012_02_13-c.pdf